FFR-CT helps determine when CAD patients face a limited risk of adverse outcomes within 3 years

New research out of Denmark suggests an advanced CT test may be able to identify when individuals with angina do not face a heightened risk of adverse outcomes within the next three years. The study's authors shared their findings in Radiology[1].

The new analysis shed light on the potential of CT angiography-derived fractional flow reserve (CT-FFR) to assess the potential impact of coronary artery disease on blood flow through the arteries, and how this measure can be predictive of negative outcomes. 

Researchers assessed the three-year clinical outcomes of patients with new-onset stable angina pectoris. Eligible participants had at least one coronary artery stenosis (narrowing) greater than 30% and did not present with atrial fibrillation or prior coronary revascularization.

Of the 900 participants, researchers compared two groups: 523 patients with normal coronary CTA-derived FFR results and 377 with abnormal results. The study's primary endpoint was a combination of all-cause death and nonfatal spontaneous heart attack.

The findings revealed that 2.1% of participants with normal FFR results experienced adverse cardiac events, while the rate was notably higher (6.6%) among those with abnormal results. This difference translated into a relative risk of 3.1, signifying a significant association. The FFR test assesses blood flow in coronary arteries, particularly in the presence of stenosis. A value of 0.80 or below indicates an abnormal test result.

A coronary artery calcium (CAC) score is a measure of plaque buildup in the heart, and a score of 400 or more signals a level that may be restricting bloodflow. Among study participants with normal CT-FFR results and a high CAC score, the adverse outcome rate was 2.2%. Participants with a high CAC score and abnormal CT-FFR results experienced adverse outcomes at a rate of 9% over the three-year timeframe. 

“Our study provides evidence for the prognostic potential of CT-FFR in patients with high CAC scores,” lead author Kristian T. Madsen, MD, PhD, with the University Hospital of Southern Denmark in Esbjerg, said in a statement. “Regardless of the patient’s baseline risk and extent of coronary artery disease measured by CAC, if CT-FFR results are normal, the prognosis is good.”

The increased risk of serious complications was significant for participants with coronary CTA-derived FFR of 0.80 or below compared to those with greater than 0.80. All-cause death occurred in 2.8% of participants, and myocardial infarction occurred in 1.3%, resulting in a total of 4.1% primary endpoint events.

“CT-FFR provides diagnostic and prognostic information beyond what can be obtained from CT angiography alone across a wide range of coronary artery calcium levels,” Madsen said. “It’s a tool that offers a lot of exciting prospects for the future.”

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Trimed Popup
Trimed Popup